BR112017008301A2 - extratos de cannabis e métodos de sua preparação e uso - Google Patents

extratos de cannabis e métodos de sua preparação e uso

Info

Publication number
BR112017008301A2
BR112017008301A2 BR112017008301A BR112017008301A BR112017008301A2 BR 112017008301 A2 BR112017008301 A2 BR 112017008301A2 BR 112017008301 A BR112017008301 A BR 112017008301A BR 112017008301 A BR112017008301 A BR 112017008301A BR 112017008301 A2 BR112017008301 A2 BR 112017008301A2
Authority
BR
Brazil
Prior art keywords
preparation
methods
bds
cannabis extracts
refers
Prior art date
Application number
BR112017008301A
Other languages
English (en)
Other versions
BR112017008301B1 (pt
Inventor
Blackmon Earnie
VERZURA Tony
Original Assignee
United Cannabis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54477280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008301(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Cannabis Corp filed Critical United Cannabis Corp
Priority to BR122021018502-6A priority Critical patent/BR122021018502B1/pt
Publication of BR112017008301A2 publication Critical patent/BR112017008301A2/pt
Publication of BR112017008301B1 publication Critical patent/BR112017008301B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a invenção refere-se à extração de componentes farmaceuticamente ativos de matérias vegetais, e mais particularmente à preparação de uma substância medicamentosa botânica (bds) para incorporação em um medicamento. ela também se refere a uma bds para uso em formulações farmacêuticas. em particular, refere-se à bds que compreende canabinoides obtidos através da extração de cannabis.
BR112017008301-9A 2014-10-21 2015-10-21 Extratos de cannabis e métodos de sua preparação e uso BR112017008301B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021018502-6A BR122021018502B1 (pt) 2014-10-21 2015-10-21 Formulação de canabinoide líquida

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462066795P 2014-10-21 2014-10-21
US62/066,795 2014-10-21
US201462068278P 2014-10-24 2014-10-24
US62/068,278 2014-10-24
PCT/US2015/056635 WO2016064987A1 (en) 2014-10-21 2015-10-21 Cannabis extracts and methods of preparing and using same

Publications (2)

Publication Number Publication Date
BR112017008301A2 true BR112017008301A2 (pt) 2017-12-19
BR112017008301B1 BR112017008301B1 (pt) 2021-12-07

Family

ID=54477280

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017008301-9A BR112017008301B1 (pt) 2014-10-21 2015-10-21 Extratos de cannabis e métodos de sua preparação e uso
BR122021018502-6A BR122021018502B1 (pt) 2014-10-21 2015-10-21 Formulação de canabinoide líquida

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122021018502-6A BR122021018502B1 (pt) 2014-10-21 2015-10-21 Formulação de canabinoide líquida

Country Status (16)

Country Link
US (4) US9730911B2 (pt)
EP (1) EP3209312A1 (pt)
JP (3) JP2017535539A (pt)
KR (1) KR20170080608A (pt)
CN (2) CN107205960A (pt)
AU (1) AU2015335997B2 (pt)
BR (2) BR112017008301B1 (pt)
CA (2) CA3135893C (pt)
CO (1) CO2017004974A2 (pt)
EA (1) EA201790880A1 (pt)
IL (1) IL251821B (pt)
MX (2) MX2017005277A (pt)
NZ (2) NZ731248A (pt)
PH (1) PH12017500733A1 (pt)
WO (1) WO2016064987A1 (pt)
ZA (2) ZA201802715B (pt)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP2018507262A (ja) 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
WO2016157192A1 (en) 2015-04-01 2016-10-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US20190062144A1 (en) * 2016-04-10 2019-02-28 Vireo Health LLC Cannabis Extract Dispensing System
CA3019338C (en) 2016-04-11 2020-12-29 Altopa, Inc. Secure portable, on-demand, microfluidic mixing and dispensing device
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
CN109152748A (zh) * 2016-05-06 2019-01-04 哈维斯特·迪莱科特企业有限公司 口服大麻药物的制造方法、组合物和医学应用
US9717683B1 (en) 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US10765713B2 (en) 2016-07-03 2020-09-08 3277991 Nova Scotia Limited Cannabis compositions and methods
KR20220132674A (ko) 2016-08-03 2022-09-30 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
CA3031810A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019523282A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
IL248150B (en) * 2016-09-29 2018-05-31 Garti Nissim A method for selective extraction of cannabinoid from plant origin
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
EP3538122A4 (en) * 2016-11-14 2020-12-02 Farm To Farma, Inc. CANNABINOID FORMULATIONS AND METHOD FOR MANUFACTURING THEREOF
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
DK3558278T3 (da) * 2016-12-22 2021-08-09 Nordiccan As Flydende cannabinoidsammensætning
USD802992S1 (en) 2017-01-16 2017-11-21 Altopa, Inc. Blend machine
CA3053187A1 (en) * 2017-02-09 2018-08-16 Bodhi Research & Development Inc. Cannabinoid-containing fatty acid formulations for treating disorders of the nervous system
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CN110799186A (zh) * 2017-03-05 2020-02-14 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 治疗炎性疾病的组合物和方法
WO2018175992A1 (en) * 2017-03-23 2018-09-27 Receptor Life Sciences Rapid and controlled delivery of compositions with restored entourage effects
EP3600271A4 (en) * 2017-03-30 2020-12-16 Ojai Energetics PBC PROCEDURES AND COMPOSITIONS FOR THE IMPROVEMENT OF HEALTH
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
CA2987979A1 (en) 2017-12-07 2019-06-07 Tresvertol Inc. Solvent-free thca extraction process
US20180343900A1 (en) * 2017-05-31 2018-12-06 Daniel Michael Leo Cannabis farming systems and methods
WO2018217803A2 (en) 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
EP3630145A4 (en) * 2017-05-31 2021-04-07 Phytecs, Inc. PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM
US10172897B2 (en) * 2017-06-06 2019-01-08 Cmg Partners, Inc. Enhanced smokable therapeutic cannabis product and method for making same
US10206888B2 (en) * 2017-06-06 2019-02-19 Cmg Partners, Inc. Cannabis-based therapeutic product for treatment of chronic pain
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
CA3065563C (en) * 2017-06-19 2023-06-13 Zelda Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
US11318179B2 (en) * 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
USD873068S1 (en) 2017-07-16 2020-01-21 Altopa, Inc. Blend device
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
US10597348B1 (en) 2017-08-21 2020-03-24 Jeff Nordahl Infusing raw cannabinoids into food oil
SG11202001725SA (en) * 2017-09-01 2020-03-30 Pureform Global Inc Synthetic cannabidiol compositions and methods of making the same
US11214765B2 (en) 2017-09-12 2022-01-04 Yakima Chief Hops, Inc Cryogenic hop lupulin or cannabis trichome pellets
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
AU2018343256B2 (en) 2017-09-28 2024-09-19 Zynerba Pharmaceuticals, Inc. Treatment of Fragile X Syndrome with cannabidiol
CA3078340A1 (en) * 2017-10-03 2019-04-11 Curo Medical Ltd. A novel cannabis production process and products thereof
PE20210251A1 (es) 2017-10-30 2021-02-09 Whistler Tech Corp Metodos y sistemas de enriquecimiento de terpenos
WO2019100168A1 (en) * 2017-11-27 2019-05-31 Enrico BOUCHARD Method of preparing a cannabis based terpene beverage and beverage thereof
US10941102B2 (en) * 2017-11-29 2021-03-09 Robert Henry Wohleb Aqueous leaching method to produce microcrystalline powder
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2019153083A1 (en) * 2018-02-12 2019-08-15 CannTrust Inc. Extraction of cannabinoids from cannabis
BR112020017023A2 (pt) 2018-02-23 2021-03-02 Nicola Michael Spirtos terapêutica à base de cannabis e método de uso
JP2021521277A (ja) * 2018-04-09 2021-08-26 エレヴェット・サイエンシズ 動物における疼痛の処置のためのアサ抽出物
EP3796903A1 (en) * 2018-05-22 2021-03-31 GBS Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation
WO2019240581A1 (en) 2018-06-14 2019-12-19 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
AU2019285379A1 (en) 2018-06-15 2021-02-04 CannPal Animal Therapeutics Limited Cannabinoid composition and methods of treatment using the same
US10639340B2 (en) 2018-06-18 2020-05-05 Eric Young Method of drying botanicals
US11591307B1 (en) * 2018-06-28 2023-02-28 Drive Foods Corp Method of processing cannabis plant matter
AU2018100925A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Cannabinoid composition and method for treating PTSD and/or anxiety
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
EP3833369A4 (en) 2018-08-08 2022-05-04 Neptune Wellness Solutions Inc. PROCESS FOR COLD EXTRACTION OF CANNABINOIDS AND TERPENES FROM CANNABIS BY ORGANIC SOLVENTS
US11254633B2 (en) 2018-10-05 2022-02-22 Jonas Alcirdas Navickas Cannabis thin layer decarboxylation
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020081357A1 (en) * 2018-10-16 2020-04-23 Golden Spice Liquors LLC Beverage compositions and methods of making and using the same
WO2020084413A1 (en) * 2018-10-23 2020-04-30 Radient Technologies Innovations Inc. Frozen biomass extraction
WO2020084427A1 (en) * 2018-10-23 2020-04-30 Radient Technologies Innovations Inc. Temperature control for active compound extraction
US20210392943A1 (en) * 2018-11-09 2021-12-23 Cronos Group Inc. Liquid composition for an electronic vapor device
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
US11243028B2 (en) 2018-12-14 2022-02-08 Fortunata, LLC Systems and methods of cryo-curing
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
US10888596B1 (en) 2018-12-28 2021-01-12 Cold Baked LLC Method of preparing Cannabis extracts
US11241468B2 (en) 2019-01-22 2022-02-08 Xiangfan JIN Method for extracting bioactive ingredient and bioactive ingredient obtained thereby
US11406593B2 (en) * 2019-01-25 2022-08-09 Nordiccan A/S Cannabinoid chewing gum with high intensity sweeteners
US11078137B1 (en) * 2019-03-08 2021-08-03 Buddies IP Holding, Inc. Sustainable terpene extraction method
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US11370767B2 (en) 2019-04-23 2022-06-28 Soma Oil Llc Cannabis processing systems and methods
US10993928B2 (en) 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
WO2020220092A1 (en) * 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
AU2020268218B2 (en) 2019-05-03 2022-09-08 Zyus Life Sciences Inc. Formulation for pain management
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
WO2020248076A1 (en) 2019-06-12 2020-12-17 Nectar Health Sciences Inc. Methods for extraction, processing, and purification of a selected family of target compounds from cannabis
US12036485B1 (en) * 2019-07-16 2024-07-16 Green Vault Systems, LLC Continuous flow cold water extraction
CA3152044A1 (en) * 2019-08-20 2021-02-25 Treehouse Biosciences, Inc. Remediated oils
BR112022003557A2 (pt) * 2019-08-27 2022-05-24 Herbolea Biotech S P A Concentrado e isolado de canabinoide, método de obtenção dos mesmos e uso dos mesmos
CA3150080A1 (en) 2019-09-06 2021-03-11 Michael Dane BACKES OPTIMIZING VOLATILE ENVIRONMENTS IN MIXTURES OF DRIED FLOWER PLANTS
WO2021050786A1 (en) * 2019-09-10 2021-03-18 California Amber Inc. Cannabin oid compositions with improved organoleptic and therapeutic properties, method of production, and use thereof
JP7326085B2 (ja) * 2019-09-19 2023-08-15 エステー株式会社 筋硬度低減剤
WO2021055886A1 (en) 2019-09-20 2021-03-25 Beaker Intellectual, Llc Isolation of cannabinoids from aqueous-extracted phytocannabinoid precipitates
US20210113490A1 (en) * 2019-10-21 2021-04-22 Avicanna Inc. Topical cannabinoid compositions for clear skin
US20210154596A1 (en) * 2019-11-21 2021-05-27 Jenny's Rose, LLC Cannabis Plant Extracts with Butane
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
EP4076485A4 (en) * 2019-12-19 2024-03-27 Steven Rothstein EXTRACTS ENRICHED WITH POLYPHENOLIC COMPOUNDS AND RELATED METHODS
US11351476B2 (en) 2020-01-07 2022-06-07 Agrify Corporation Method for chemical separation of cannabinoids
US20210213406A1 (en) * 2020-01-09 2021-07-15 Willamette Valley Alchemy Method and Apparatus for Curing Plant-Based Extracts
EP4087592A1 (en) 2020-01-10 2022-11-16 Real Isolates, LLC Methods for obtaining compounds from a plant or fungus material, respective compositions, and uses thereof
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021231950A1 (en) * 2020-05-14 2021-11-18 Azdt Holdings, Llc Apparatus for cannabinol generation and methods of using the same
IT202000012448A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
IT202000012463A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
KR102388396B1 (ko) 2020-07-06 2022-04-20 안동시 대마 줄기 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR102388399B1 (ko) 2020-07-06 2022-04-20 안동시 대마 뿌리 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20220005153A (ko) 2020-07-06 2022-01-13 안동시 대마 뿌리 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20220005155A (ko) 2020-07-06 2022-01-13 안동시 대마 줄기 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20220036035A (ko) 2020-09-15 2022-03-22 안동대학교 산학협력단 대마 잎 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
US11612627B2 (en) 2020-09-15 2023-03-28 Andong National University Industry-Academic Cooperation Foundation Method for preventing or treating thrombosis
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
KR102593702B1 (ko) * 2021-04-12 2023-10-25 농업회사법인 제이헴프코리아 주식회사 탈지대마씨앗 분말의 제조방법
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
GB202109021D0 (en) * 2021-06-23 2021-08-04 Ldn Pharma Ltd Treatment for autoimmune diseases
KR102346700B1 (ko) * 2021-07-30 2021-12-31 강원대학교산학협력단 대마로부터 고 함량의 칸나비디올을 대량생산하는 방법
US20230159483A1 (en) * 2021-11-24 2023-05-25 Dominick Monaco Cannabidiol extraction and conversion process
KR20230117982A (ko) 2022-02-03 2023-08-10 주식회사 네오켄바이오 칸나비노이드 추출물의 제조방법 및 칸나비노이드 추출물의 분석 방법
US11911427B2 (en) 2022-03-12 2024-02-27 Wilhelm Rumpf Extraction and infusion of active components from plant materials
CN114788480B (zh) * 2022-05-13 2023-02-03 黑龙江省农业科学院经济作物研究所 一种北方药用工业大麻花叶冻干收获方法
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same
WO2024015780A1 (en) 2022-07-11 2024-01-18 Ilera Therapeutics Llc Zlt-007 and methods of treating diabetic neuropathy
KR20240077705A (ko) 2022-11-25 2024-06-03 주식회사 엔에프씨 대마로부터 고함량의 칸나비디올을 추출하는 방법
WO2024155927A1 (en) * 2023-01-20 2024-07-25 Biopharmaceutical Research Company Cannabinoid compositions, and uses thereof in treatment of neurodegenerative diseases or disorders and cancers

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US5434295A (en) 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5773075A (en) 1996-12-13 1998-06-30 Kalamazoo Holdings, Inc. High temperature countercurrent solvent extraction of Capsicum solids
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
NZ527289A (en) 2001-02-14 2005-05-27 Gw Pharma Ltd Lipophilic medicaments and their administration via mucosal surfaces
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20030050334A1 (en) * 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
US20030017216A1 (en) 2001-07-23 2003-01-23 Schmidt Robert Gustav Isolation of herbal and cannabinoid medicinal extracts
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
US20080057117A1 (en) 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
AU2003250372A1 (en) 2002-06-22 2004-01-06 Norton Healthcare Limited Pharmaceutical composition
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
ES2592531T3 (es) 2002-08-14 2016-11-30 Gw Pharma Limited Extracción de canabinoides farmacéuticamente activos de materiales vegetales
SI1542657T1 (sl) 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
CA2503310A1 (en) * 2005-04-08 2006-10-08 Antony Paul Hornby Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
CN102246992A (zh) * 2010-12-23 2011-11-23 东莞市德亨饮料食品有限公司 一种火麻仁杏仁露饮料及其制备方法
US20120264818A1 (en) * 2011-04-15 2012-10-18 Jon Newland Topical Compositions with Cannabis Extracts
WO2013009928A1 (en) 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
DK2844243T3 (da) * 2012-05-03 2020-02-03 Echo Pharmaceuticals Bv Fremgangsmåde til fremstilling af et cannabisplante-isolat omfattende delta-9-tetrahydrocannabinol
CN104363890B (zh) * 2012-05-07 2018-01-26 回音制药公司 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元
EP2934512B1 (en) 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
BR112015020332A2 (pt) 2013-02-28 2017-07-18 Full Spectrum Laboratories Ltd processos de engenharia química e aparelhos para a síntese de compostos
CA2904968A1 (en) * 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
AU2014347807A1 (en) 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
EP3071193B1 (en) 2013-11-20 2020-01-08 Panag Pharma Inc. Compositions and methods for treatment of ocular inflammation and pain
US20170340562A9 (en) 2014-05-12 2017-11-30 Hddc Holdings Llc Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US20160039591A1 (en) 2014-07-22 2016-02-11 Craig E. Kinzer Packaging systems, devices, methods, and composition including cannabinoid unit dose forms
US20160081975A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Soft gel compositions and pre-gel concentrates
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN107205960A (zh) * 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法

Also Published As

Publication number Publication date
MX2023007033A (es) 2023-06-28
US20220218657A1 (en) 2022-07-14
BR112017008301B1 (pt) 2021-12-07
CA2965493C (en) 2021-12-07
MX2017005277A (es) 2018-01-11
PH12017500733A1 (en) 2017-10-09
EA201790880A1 (ru) 2017-08-31
JP2023078465A (ja) 2023-06-06
CA2965493A1 (en) 2016-04-28
KR20170080608A (ko) 2017-07-10
CA3135893A1 (en) 2016-04-28
CN107205960A (zh) 2017-09-26
NZ769177A (en) 2024-04-26
ZA201802715B (en) 2019-09-25
AU2015335997A1 (en) 2017-05-18
WO2016064987A1 (en) 2016-04-28
IL251821A0 (en) 2017-06-29
US20160106705A1 (en) 2016-04-21
CN113509499A (zh) 2021-10-19
NZ731248A (en) 2024-04-26
BR122021018502B1 (pt) 2022-05-03
US20170360745A1 (en) 2017-12-21
JP2017535539A (ja) 2017-11-30
US10555928B2 (en) 2020-02-11
CA3135893C (en) 2023-11-14
EP3209312A1 (en) 2017-08-30
AU2015335997B2 (en) 2020-10-01
CO2017004974A2 (es) 2017-11-10
US9730911B2 (en) 2017-08-15
US11291650B2 (en) 2022-04-05
IL251821B (en) 2021-02-28
US20200215026A1 (en) 2020-07-09
ZA201902584B (en) 2024-09-25
JP2021042233A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
MX2018013504A (es) Metodos de fabricacion, composiciones y aplicaciones medicas de productos farmaceuticos de cannabis administrables oralmente.
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
CO2019001043A2 (es) Composición de cannabis
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
NZ726746A (en) Stable cannabinoid formulations
BR112018003892A2 (pt) ?composição farmacêutica e método para a redução da gordura?
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CO2017002682A2 (es) Composiciones y métodos para recubrimientos cannabinoides para uso en la entrega de fármacos
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
ZA202108771B (en) Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
BR112017009510A2 (pt) composições compreendendo ciclosporina
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
BR112017019364A2 (pt) dispersões sólidas
BR112017009848A2 (pt) combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica.
BR112018010489A8 (pt) tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos
MX2016010577A (es) Inhaladores de dosis medida presurizados y metodo de fabricacion.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2015, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 8A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2745 DE 15-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.